How does a GLP-1 receptor agonist behave on a C8 column compared to mazdutide?

Numbers first: a GLP-1 receptor agonist · a C8 column · mazdutide.

I want to know what the trade-off actually is rather than which option is fashionable.

I would rather have a defensible reason than a marginal improvement.

What does each option buy me, and what does it cost me?

The underlying point is that the limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.

Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.

Stated carefully, sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.